

## CHAPTER II EXPERIMENTAL

### Instruments and Equipment

Melting points were determined with a Fishers-Johns melting point apparatus and are uncorrected. Thin layer chromatography (TLC) was performed on aluminium sheets pre-coated with silica gel (Merck's, Kieselgel 60 F<sub>254</sub>) and column chromatography was performed on silica gel Merck's silica gel 60 G Art 7734 (70-230 mesh) were used as adsorbents for column chromatography.

The IR spectra were recorded on NICOLET IMPACT 410 FT/IR spectrophotometer. Solid samples were incorporated into a pellet of potassium bromide. Liquid samples were dropped on sodium chloride plates. The <sup>1</sup>H- and <sup>13</sup>C-NMR spectra were performed in deuterated chloroform (CDCl<sub>3</sub>) or deuterated dimethylsulfoxide (DMSO-d<sub>6</sub>) with tetramethylsilane (TMS) as an internal reference on a Fourier Transform Nuclear Magnetic Resonance Spectrometer of Bruker model AC-F 200 which was operated at 200.13 MHz for <sup>1</sup>H and 50.32 MHz for <sup>13</sup>C nuclei.

### Chemicals

All solvents used in this research were purified prior to use by standard methodology except for those which were reagent grades. The reagents used for synthesis were purchased from Fluka Chemical Company or otherwise stated and were used without further purification.

### General Procedure for the Synthesis of Amide

#### *Step I:*


A solution of triphenylphosphine (PPh<sub>3</sub>) 2 eq (6 mmol, 1.57 g) in CH<sub>2</sub>Cl<sub>2</sub> 3 mL was added to a mixture of carboxylic acid 1 eq (3 mmol) and trichloroacetonitrile (Cl<sub>3</sub>CCN) 2 eq (6 mmol, 0.6 mL) in CH<sub>2</sub>Cl<sub>2</sub> 3 mL at room temperature. The mixture was stirred for 1 hour.

#### *Step II:*

A mixture of amine 1 eq (3 mmol) and 3 eq (9 mmol, 1.25 mL) of triethylamine (Et<sub>3</sub>N) was added to the above mixture. The reaction continued stirring

for another 20 minutes at room temperature. When the reaction was completed (monitoring by TLC), the mixture was extracted with 10% HCl and saturated aqueous NaHCO<sub>3</sub>, respectively, and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After evaporation, the mixture was separated with column chromatography on silica gel (eluent : hexane-EtOAc 8:2) and recrystallized with CH<sub>2</sub>Cl<sub>2</sub> and hexane to yield the desired amide.

### Benzanilide Synthesis (Compound C1)



The general procedure was followed by using benzoic acid and aniline. After column chromatography separation, benzanilide as white needle crystal 0.44 g (75 %) was obtained, m.p. 164-165 °C (CH<sub>2</sub>Cl<sub>2</sub>-hexane) (lit.<sup>44</sup> 163 °C), R<sub>f</sub> 0.63 (50 % EtOAc/hexane). IR (KBr): 3347, 3056, 1659, 1596, 1436 and 1315 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 1.61 (s, 1H, NH) and 7.14-7.87 (m, 10H, ArH); <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ (ppm): 120.3 (2C, Cb' and Cf'), 124.6 (1C, Cd'), 127.1 (2C, Cc and Cg), 128.8 (2C, Cd and Cf), 129.1 (2C, Cc' and Ce'), 131.8 (1C, Ce), 135.0 (1C, Cb), 137.9 (1C, Ca') and 165.9 (1C, Ca).

### Study on the Optimum Conditions

#### 1. Influence of Cl<sub>3</sub>CCN and PPh<sub>3</sub> Ratio

The ratios of Cl<sub>3</sub>CCN and PPh<sub>3</sub> for the synthesis of benzanilide utilizing the general procedure were varied (benzoic acid was fixed at 1 eq). The variations of the Cl<sub>3</sub>CCN and PPh<sub>3</sub> ratios are as follows: 1:1, 1:2, 1:3, 1:4, 1:5, 2:0, 2:1, 2:2, 2:3, 2:4, 2:5, 3:1, 4:1, 5:1, 0:2, 3:2, 4:2 and 5:2, respectively. Determine the yield of benzanilide.

#### 2. Influence of Time and Temperature

Employing the above-mentioned general procedure, but the reaction was operated by altering time and temperature in step I.

- 2.1. Time variation: The reaction was carried out at room temperature (25-30 °C) for 0.5, 1, 1.5, 2 and 3 h, respectively.
- 2.2. Temperature variation: The reaction was performed by using an ice water bath (0-5 °C) for 0.5, 1, 1.5, 2 and 3 h, respectively.

### 3. Influence of Solvent System


Solvents for the synthesis of benzanilide according to the general procedure were varied by using chloroform ( $\text{CHCl}_3$ ), carbon tetrachloride ( $\text{CCl}_4$ ), ethyl acetate ( $\text{EtOAc}$ ), 1,2-dichloroethane (1,2-DCE), tetrahydrofuran (THF), toluene, acetonitrile, acetone, 1:1 THF- $\text{CHCl}_3$ , 1:1 acetone- $\text{CHCl}_3$ , 1:1 ether- $\text{CHCl}_3$  and 1:1 methanol ( $\text{MeOH}$ )- $\text{CHCl}_3$  instead of  $\text{CH}_2\text{Cl}_2$ .

### 4. Influence of Chlorinated Reagent

Reagents for the synthesis of benzanilide according to the general procedure were altered by employing carbon tetrachloride ( $\text{CCl}_4$ ), trichloroacetic acid ( $\text{Cl}_3\text{CCO}_2\text{H}$ ), ethyl trichloroacetate ( $\text{Cl}_3\text{CCO}_2\text{Et}$ ), trichloroethanol ( $\text{Cl}_3\text{CCH}_2\text{OH}$ ), 2-chloroacetamide ( $\text{ClCH}_2\text{C}(\text{O})\text{NH}_2$ ), trichloroacetamide ( $\text{Cl}_3\text{CC}(\text{O})\text{NH}_2$ ), bromotrichloromethane ( $\text{Cl}_3\text{CBr}$ ), trifluoroacetic acid ( $\text{F}_3\text{CCO}_2\text{H}$ ), hexachloroethane ( $\text{Cl}_3\text{CCCl}_3$ ) and hexachloro-2-propanone ( $\text{Cl}_3\text{CC}(\text{O})\text{CCl}_3$ ) instead of  $\text{Cl}_3\text{CCN}$ .

### Carboxylic Acid Variation

In order to overview the scope of this developed procedure, various amides were prepared using general procedure by using aniline as a representative amine reacting with various carboxylic acids, namely salicylic acid, acetylsalicylic acid, 4-methoxybenzoic acid, 4-nitrobenzoic acid, *trans*-cinnamic acid, palmitic acid, 3-bromopropionic acid and phthalic acid. The details and characteristic spectral data are presented as follows.


**2-Hydroxy-N-phenylbenzamide (Compound C2)****Method A (Compound C2a) :**

The general procedure was employed using salicylic acid to afford compound **C2** as white plate crystal, 0.35 g (55 %), m.p. 133-135 °C (CH<sub>2</sub>Cl<sub>2</sub>-hexane) (lit.<sup>44</sup> 135 °C), R<sub>f</sub> 0.62 (50 % EtOAc/hexane). IR (KBr): 3675-3356, 3308, 3066, 1688, 1644, 1446 and 1301 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 1.72 (s, 1H, NH), 6.52-8.05 (m, 9H, ArH) and 11.98 (s, 1H, OH); <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ (ppm): 114.6 (1C, Cd), 118.9 (2C, Cb' and Cf), 119.0 (1C, Cb), 121.2 (1C, Cf), 125.4 (1C, Cd'), 129.2 (3C, Cg, Cc' and Ce'), 134.7 (1C, Ce), 136.6 (1C, Ca'), 161.8 (1C, Cc) and 168.4 (1C, Ca).

**Method B (Compound C2b) :**


The general procedure was followed starting from acetylsalicylic acid to afford compound **C2**-acetate as white needle crystal, 0.38 g (49 %). The derived *N*-acetylsalicyloyl compound was hydrolyzed by dissolving in 0.1 N NaOH and kept at room temperature for 10 minutes. Addition of 0.1 N HCl precipitated the desired compound. The precipitate was recrystallized by a mixture of CH<sub>2</sub>Cl<sub>2</sub>-hexane to yield white plate crystal, 0.31 g (49 %), m.p. 134-135 °C (CH<sub>2</sub>Cl<sub>2</sub>-hexane) (lit.<sup>44</sup> 135 °C), R<sub>f</sub> 0.62 (50 % EtOAc/hexane). IR (KBr): 3678-3347, 3309, 3063, 1689, 1645, 1447 and 1307 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 1.56 (s, 1H, NH), 6.91-7.92 (m, 9H, ArH) and 11.97 (s, 1H, OH); <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ (ppm): 114.6 (1C, Cd), 118.9 (2C, Cb' and Cf), 119.0 (1C, Cb), 121.3 (1C, Cf), 125.4 (1C, Cd'), 129.2 (3C, Cg, Cc' and Ce'), 134.7 (1C, Ce), 136.6 (1C, Ca'), 161.8 (1C, Cc) and 168.4 (1C, Ca).

**4-Methoxy-N-phenylbenzamide (Compound C3)**




White needle crystal, 0.45 g (66 %), m.p. 171-173 °C (CH<sub>2</sub>Cl<sub>2</sub>-hexane) (lit.<sup>44</sup> 171 °C), R<sub>f</sub> 0.73 (50 % EtOAc/hexane). IR (KBr): 3337, 3052, 2839, 1659, 1596, 1431 and 1315 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 1.59 (s, 1H, NH), 3.85 (s, 3H, OCH<sub>3</sub>), 6.95 (d, J = 8.82 Hz, 2H, Hd and Hf), 7.12 (t, J = 7.37 Hz, 1H, Hd'), 7.35 (t, J = 7.47, 2H, Hc' and He'), 7.61 (d, J = 7.48 Hz, 2H, Hb' and Hf') and 7.83 (d, J = 8.89 Hz, 2H, Hc and Hg); <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ (ppm): 55.5 (1C, OCH<sub>3</sub>), 114.0 (2C, Cd and Cf), 120.1 (2C, Cb' and Cf'), 124.3 (1C, Cd'), 127.1 (1C, Cb), 128.9 (2C, Cc and Cg), 129.1 (2C, Cc' and Ce'), 138.1 (1C, Ca'), 162.5 (1C, Ca) and 165.2 (1C, Ce).


**4-Nitro-N-phenylbenzamide (Compound C4)**




White needle crystal, 0.36 g (49 %), m.p. 213-214 °C (CH<sub>2</sub>Cl<sub>2</sub>-hexane) (lit.<sup>44</sup> 211 °C), R<sub>f</sub> 0.67 (50 % EtOAc/hexane). IR (KBr): 3318, 3081, 1654, 1596, 1528, 1436, 1349 and 1315 cm<sup>-1</sup>; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ (ppm): 1.55 (s, 1H, NH), 7.13 (t, J = 7.38 Hz, 1H, Hd'), 7.37 (t, J = 7.50 Hz, 2H, Hc' and He'), 7.76 (d, J = 7.56 Hz, 2H, Hb' and Hf'), 8.17 (d, J = 8.92 Hz, 2H, Hc and Hg) and 8.36 (d, J = 8.91 Hz, 2H, Hd and Hf); <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>) δ (ppm): 126.2 (2C, Cb' and Cf'), 129.3 (2C, Cd and Cf), 129.9 (1C, d'), 134.5 (2C, Cc and Cg), 134.9 (2C, Cc' and Ce'), 144.4 (1C, Ca'), 146.4 (1C, Cb), 154.9 (1C, Ce) and 169.6 (1C, Ca).

**3,N-Diphenyl-2-propenamide (Compound C5)**


White needle crystal, 0.46 g (68 %), m.p. 154-156 °C (CH<sub>2</sub>Cl<sub>2</sub>-hexane) (lit.<sup>44</sup> 153 °C), R<sub>f</sub> 0.61 (50 % EtOAc/hexane). IR (KBr): 3332, 3047, 1951, 1659, 1620, 1528, 1436 and 1339 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 1.78 (s, 1H, NH), 6.62 (d, J = 15.55 Hz, 1H, HC=CHCO), 7.14-7.87 (m, 10H, ArH) and 7.73 (d, J = 15.57 Hz, 1H, CH=CHCO); <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ (ppm): 120.2 (1C, C<sub>b</sub>), 121.0 (2C, C<sub>b'</sub> and C<sub>f'</sub>), 124.5 (1C, C<sub>d'</sub>), 128.0 (2C, C<sub>e</sub> and C<sub>i</sub>), 128.8 (1C, C<sub>g</sub>), 129.0 (2C, C<sub>f</sub> and C<sub>h</sub>), 129.9 (2C, C<sub>c'</sub> and C<sub>e'</sub>), 134.6 (1C, C<sub>d</sub>), 138.1 (1C, C<sub>a'</sub>), 142.3 (1C, C<sub>c</sub>) and 164.4 (1C, C<sub>a</sub>).

**N-Phenylhexadecanamide (Compound C6)**

White needle crystal, 0.68 g (68 %), m.p. 88-89 °C (CH<sub>2</sub>Cl<sub>2</sub>-hexane) (lit.<sup>44</sup> 90 °C), R<sub>f</sub> 0.79 (50 % EtOAc/hexane). IR (KBr): 3303, 3056, 2916, 1659, 1601, 1538, 1441 and 1375 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 0.86 (t, J = 6.23 Hz, 3H, CH<sub>3</sub>), 1.05-1.30 (s (br), 24H, (CH<sub>2</sub>)<sub>12</sub>CH<sub>3</sub>), 1.54 (s, 1H, NH), 1.68-1.75 (m, 2H, CH<sub>2</sub>CH<sub>2</sub>CO), 2.33 (t, J = 7.41 Hz, 2H, CH<sub>2</sub>CO) and 7.08-7.52 (m, 5H, ArH); <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ (ppm): 14.1 (1C, C<sub>p</sub>), 22.7 (1C, C<sub>o</sub>), 25.7 (1C, C<sub>c</sub>), 29.5 (10C, C<sub>d</sub>-C<sub>m</sub>), 31.9 (1C, C<sub>n</sub>), 37.8 (1C, C<sub>b</sub>), 119.8 (2C, C<sub>b'</sub> and C<sub>f'</sub>), 124.1 (1C, C<sub>d'</sub>), 129.0 (2C, C<sub>c'</sub> and C<sub>e'</sub>), 138.0 (1C, C<sub>a'</sub>) and 171.5 (1C, C<sub>a</sub>).

**3-Bromo-N-phenylpropanamide (Compound C7)**

White plate crystal, 0.25 g (37 %), m.p. 120-121 °C (CH<sub>2</sub>Cl<sub>2</sub>-hexane) (lit.<sup>45</sup> 119-120 °C), R<sub>f</sub> 0.54 (50 % EtOAc/hexane). IR (KBr): 3304, 3192, 2979, 1657, 1552, 1441 and 1310 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 1.61 (s, 1H, NH), 2.79 (t, J = 6.43 Hz, 2H, CH<sub>2</sub>), 3.86 (t, J = 6.42 Hz, 2H, CH<sub>2</sub>Br) and 7.07-7.52 (m, 5H, ArH); <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ (ppm): 27.6 (1C, Cc), 40.4 (1C, Cb), 120.6 (2C, Cb' and Cf'), 125.2 (1C, Cd'), 129.6 (2C, Cc' and Ce'), 140.1 (1C, Ca') and 174.6 (1C, Ca).


**N,N'-Diphenylphthalamide (Compound C8)**

The general procedure was repeated by using phthalic acid and two-fold amounts of reagents: Cl<sub>3</sub>CCN, PPh<sub>3</sub>, aniline and Et<sub>3</sub>N to gain yellow needle crystal, 0.33 g (34 %), m.p. 251-253 °C decomp. (CH<sub>2</sub>Cl<sub>2</sub>-hexane) (lit.<sup>44</sup> 251 °C decomp.), R<sub>f</sub> 0.60 (50 % EtOAc/hexane). IR (KBr): 3463, 3015, 1709, 1589, 1490 and 1375 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 1.54 (s, 2H, NH) and 7.39-7.97 (m, 15H, ArH); <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ (ppm): 119.3 (2C, Cb' and Cf'), 119.5 (2C, Cb'' and Cf''), 123.3 (1C, Cd'), 123.4 (1C, Cd''), 127.7 (2C, Cc and Cf), 129.3 (2C, Cc' and Ce'), 129.5 (2C, Cc'' and Ce''), 131.7 (2C, Cd and Ce), 134.7 (2C, Cb and Cg), 138.9 (1C, Ca'), 139.5 (1C, Ca''), 167.3 (1C, Ca) and 167.4 (1C, Ch).

### Amine Variation


Various amides were prepared using aforementioned general procedure by fixing benzoic acid as a representative carboxylic acid and varied amines, namely *N*-phenylaniline, benzylamine, cyclohexylamine, *i*-butylamine and *n*-butylamine. The details and characteristic spectral data are presented as follows.

#### *N,N*-Diphenylbenzamide (Compound A1)




Yellow prism, 0.05 g (7 %), m.p. 177-179 °C (CH<sub>2</sub>Cl<sub>2</sub>-hexane) (lit.<sup>44</sup> 179-180 °C), R<sub>f</sub> 0.32 (CH<sub>2</sub>Cl<sub>2</sub>). IR (KBr): 3061, 1659, 1601, 1499, 1446 and 1354 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 7.12-7.46 (m, 15H, ArH); <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ (ppm): 126.3 (4C, C<sub>b</sub>', C<sub>f</sub>', C<sub>b</sub>'' and C<sub>f</sub>''), 127.5 (2C, C<sub>d</sub>' and C<sub>d</sub>''), 127.9 (2C, C<sub>c</sub> and C<sub>g</sub>), 129.1 (2C, C<sub>d</sub> and C<sub>f</sub>), 129.5 (4C, C<sub>c</sub>', C<sub>e</sub>', C<sub>c</sub>'' and C<sub>e</sub>''), 130.2 (1C, C<sub>e</sub>), 136.1 (1C, C<sub>b</sub>), 143.9 (2C, C<sub>a</sub>' and C<sub>a</sub>'') and 170.6 (1C, C<sub>a</sub>).

#### *N*-Methylphenylbenzamide (Compound A2)




White needle crystal, 0.49 g (77 %), m.p. 103-104 °C (CH<sub>2</sub>Cl<sub>2</sub>-hexane) (lit.<sup>44</sup> 105-106 °C), R<sub>f</sub> 0.51 (50 % EtOAc/hexane). IR (KBr): 3289, 3085-3027, 2926, 1639, 1601, 1593, 1489, 1451 and 1417 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 1.63 (s, 1H, NH), 4.64 (d, J = 5.65 Hz, 2H, CH<sub>2</sub>NH) and 7.24-7.80 (m, 10H, ArH); <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ (ppm): 44.0 (1C, C<sub>a</sub>'), 127.1 (1C, C<sub>e</sub>'), 127.5 (2C, C<sub>c</sub>' and C<sub>g</sub>'), 127.8 (2C, C<sub>c</sub> and C<sub>g</sub>), 128.5 (2C, C<sub>d</sub>' and C<sub>f</sub>'), 128.7 (2C, C<sub>d</sub> and C<sub>f</sub>), 131.5 (1C, C<sub>e</sub>), 134.4 (1C, C<sub>b</sub>), 138.4 (1C, C<sub>b</sub>') and 167.6 (1C, C<sub>a</sub>).




***N-Cyclohexylbenzamide*** (Compound A3)


White needle crystal, 0.54 g (89 %), m.p. 147-149 °C (CH<sub>2</sub>Cl<sub>2</sub>-hexane) (lit.<sup>44</sup> 147 °C), R<sub>f</sub> 0.55 (50 % EtOAc/hexane). IR (KBr): 3313, 3081-3032, 2935, 2853, 1625, 1576, 1489 and 1330 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 1.12-2.04 (m, 10H, alkyl group), 3.89-4.03 (m, 1H, NHCH), 5.94 (s (br), 1H, NH) and 7.24-7.77 (m, 5H, ArH); <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ (ppm): 24.9 (2C, Cc' and Ce'), 25.6 (1C, Cd'), 33.2 (2C, Cb' and Cf'), 48.7 (1C, Ca'), 126.8 (2C, Cc and Cg), 128.5 (2C, Cd and Cf), 131.2 (1C, Ce), 135.1 (1C, Cb) and 166.7 (1C, Ca).

***N-i-Butylbenzamide*** (Compound A4)

Light yellow liquid, 0.43 g (80 %), R<sub>f</sub> 0.44 (50 % EtOAc/hexane). IR (neat): 3588-3192, 3066, 2965-2873, 1644, 1583, 1552, 1485 and 1310 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 0.86 (d, J = 6.69 Hz, 6H, CH<sub>3</sub>), 1.75-1.89 (m, 1H, CH(CH<sub>3</sub>)<sub>2</sub>), 2.06 (s, 1H, NH), 3.15 (t, J = 6.85 Hz, 2H, NHCH<sub>2</sub>) and 7.24-7.76 (m, 5H, ArH); <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ (ppm): 20.2 (2C, Cc' and Cd'), 28.5 (1C, Cb'), 47.4 (1C, Ca'), 127.0 (2C, Cc and Cg), 128.7 (2C, Cd and Cf), 131.2 (1C, Ce), 134.9 (1C, Cb), and 167.9 (1C, Ca).


***N-n-Butylbenzamide* (Compound A5)**

Deep yellow liquid, 0.33 g (61 %),  $R_f$  0.56 (50 % EtOAc/hexane). IR (neat): 3584-3148, 3066, 2965-2873, 1639, 1601, 1543, 1485 and 1315  $\text{cm}^{-1}$ ;  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  (ppm): 0.89 (t,  $J = 7.11$  Hz, 3H,  $\text{CH}_3$ ), 1.23-1.43 (m, 2H,  $\text{CH}_2\text{CH}_3$ ), 1.51-1.62 (m, 2H,  $\text{NHCH}_2\text{CH}_2$ ), 2.24 (s (br), 1H,  $\text{NH}$ ), 3.33-3.43 (q,  $J = 6.86$  Hz, 2H,  $\text{NHCH}_2$ ) and 7.24-7.76 (m, 5H,  $\text{ArH}$ );  $^{13}\text{C-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  (ppm): 13.8 (1C,  $\text{Cd}'$ ), 20.1 (1C,  $\text{Cc}'$ ), 31.7 (1C,  $\text{Cb}'$ ), 39.8 (1C,  $\text{Ca}'$ ), 126.9 (2C,  $\text{Cc}$  and  $\text{Cg}$ ), 128.5 (2C,  $\text{Cd}$  and  $\text{Cf}$ ), 131.3 (1C,  $\text{Ce}$ ), 134.8 (1C,  $\text{Cb}$ ), and 167.7 (1C,  $\text{Ca}$ )

**Preparation of Starting Compounds*****Acetylsalicylic Acid* (Compound S1)**


Five drops of concentrated sulfuric acid were added to a mixture of 1 g (0.0725 mol) of dry salicylic acid and 1.4 mL (0.0147 mol) of acetic anhydride. The mixture was warmed on a water bath to about 50-60  $^{\circ}\text{C}$  and stirred for 15 minutes. After that, 15 mL of hot ethanol was added to a mixture. The mixture was poured into 7.5 mL of warm water to precipitate the desired compound. The precipitate was recrystallized by a mixture of ether-hexane to give white needle crystal 2.26 g (85 %), m.p. 133-134  $^{\circ}\text{C}$  (ether-hexane) (lit.<sup>46</sup> 134-136  $^{\circ}\text{C}$ ),  $R_f$  0.5 (methanol). IR (KBr): 3308-3544, 1760, 1605, 1460, 1306 and 1185  $\text{cm}^{-1}$ ;  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  (ppm): 2.33 (s, 3H,  $\text{CH}_3$ ), 5.08 (s, 1H,  $\text{OH}$ ), 7.12 (d,  $J = 7.95$  Hz, 1H,  $\text{Hd}$ ), 7.33 (t,  $J = 7.77$  Hz, 1H,  $\text{Hf}$ ), 7.60 (t,  $J = 7.58$  Hz, 1H,  $\text{He}$ ) and 8.09 (d,  $J = 7.86$  Hz, 1H,  $\text{Hg}$ );  $^{13}\text{C-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  (ppm): 21.0 (1C,  $\text{CH}_3$ ), 122.2 (1C,  $\text{Cd}$ ), 124.0 (1C,  $\text{Cb}$ ), 126.2 (1C,  $\text{Cf}$ ), 132.5 (1C,  $\text{Cg}$ ), 134.9 (1C,  $\text{Ce}$ ), 151.3 (1C,  $\text{Cc}$ ), 169.8 (1C,  $\text{Ch}$ ) and 170.1 (1C,  $\text{Ca}$ ).

### 3,4-Dioxymethylene-cinnamic Acid (Compound S2)



After 3,4-dioxymethylenebenzaldehyde 4.50 g (0.03 mol) and piperidine 0.28 mL were added to a solution of malonic acid 3.29 g (0.03 mol) in 5.2 mL of pyridine, the mixture was refluxed for 2 hours. When the reaction was completed (checked by TLC), it was added into a mixture of ice 16 g, conc. HCl 8 mL and water 26 mL for precipitating the desired compound. The solid was filtered and washed with water until no more acid remained (checked by litmus paper). The solid was crystallized by ethanol to give white needle crystal 3.15 g (55 %), m.p. 239-241 °C (EtOH) (lit<sup>44</sup> 242 °C),  $R_f$  0.64 (EtOH). IR (KBr): 3385-2350, 1693, 1625, 1489, 1446, 1320 and 1248  $\text{cm}^{-1}$ ;  $^1\text{H-NMR}$  (DMSO- $d_6$ )  $\delta$  (ppm): 3.33 (s, 1H, OH), 6.06 (s, 2H, OCH<sub>2</sub>O), 6.38 (d,  $J = 15.92$  Hz, 1H, CH=CHCO), 6.93 (d,  $J = 8.03$  Hz, 1H, H<sub>h</sub>), 7.15 (d,  $J = 7.90$  Hz, 1H, H<sub>i</sub>), 7.36 (s, 1H, H<sub>e</sub>) and 7.49 (d,  $J = 15.73$  Hz, 1H, CH=CHCO);  $^{13}\text{C-NMR}$  (DMSO- $d_6$ )  $\delta$  (ppm): 101.5 (1C, OCH<sub>2</sub>O), 106.6 (1C, C<sub>e</sub>), 108.4 (1C, C<sub>h</sub>), 117.0 (1C, C<sub>b</sub>), 124.6 (1C, C<sub>i</sub>), 128.6 (1C, C<sub>d</sub>), 143.8 (1C, C<sub>c</sub>), 148.0 (1C, C<sub>g</sub>), 149.1 (1C, C<sub>f</sub>) and 167.8 (1C, C<sub>a</sub>).

### 3,4,5-Trimethoxycinnamic Acid (Compound S3)



The procedure for the synthesis of Compound S2 was repeated by employing 3,4,5-trimethoxybenzaldehyde instead of 3,4-dioxymethylenebenzaldehyde. Light yellow needle crystal 2.49 g (35 %) was obtained, m.p. 122-123 °C (EtOH) (lit<sup>44</sup> 127 °C),  $R_f$  0.45 (EtOAc). IR (KBr): 3462-2731, 2861, 1702, 1629, 1504, 1412 and 1344  $\text{cm}^{-1}$ ;  $^1\text{H-NMR}$  (CDCl<sub>3</sub>)  $\delta$  (ppm): 3.86 (s, 9H, OCH<sub>3</sub>), 6.33 (d,  $J = 15.92$  Hz, 1H, HC=CHCO), 6.75 (s, 2H, ArH) and 7.68 (d,  $J = 15.85$  Hz, 1H, CH=CHCO);  $^{13}\text{C-NMR}$  (CDCl<sub>3</sub>)  $\delta$  (ppm): 56.1 (2C, C<sub>j</sub> and C<sub>l</sub>), 61.0 (1C, C<sub>k</sub>), 105.5 (2C, C<sub>e</sub> and C<sub>i</sub>),


116.5 (1C, Cb), 129.5 (1C, Cd), 140.5 (1C, Cg), 147.0 (1C, Cc), 153.4 (2C, C<sup>f</sup> and Ch) and 172.4 (1C, Ca).

### General Procedure for the Synthesis of Target Molecules


A mixture of carboxylic acid 1 eq (3 mmol) and Cl<sub>3</sub>CCN 1 eq (3 mmol, 0.3 mL) in CHCl<sub>3</sub> 3 mL was treated with a solution of PPh<sub>3</sub> 2 eq (6 mmol, 1.58 g) in CHCl<sub>3</sub> 3 mL at 0-5° C by using ice water bath. After stirred for 2 hours, a mixture of amine 1 eq (3 mmol) and 3 eq (9 mmol, 1.25 mL) of Et<sub>3</sub>N was added. The reaction mixture was continued stirring for another 2 hours at room temperature. When the reaction was completed, the mixture was extracted with 10% HCl and saturated aqueous NaHCO<sub>3</sub>, respectively, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated to give the crude product which was further purified with column chromatography on silica gel (eluent: hexane-EtOAc 8:2).

### Synthesis of Target Molecules


#### *Osalmid* (Compound T1)




White needle 0.32 g (47 %), m.p. 176-178 °C (MeOH/H<sub>2</sub>O) (lit.<sup>47</sup> 178 °C), R<sub>f</sub> 0.48 (50 % EtOAc/hexane). IR (KBr): 3601-3352, 3298, 3039, 1615, 1550, 1505, 1445 and 1331 cm<sup>-1</sup>; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ (ppm): 1.78 (s, 1H, NH), 6.91 (s, 1H, Hg'), 6.97 (d, J = 7.76 Hz, 2H, Hc' and He'), 7.13 (t, J = 8.10 Hz, 1H, Hf), 7.34 (d, J = 8.08 Hz, 1H, Hd), 7.42 (t, J = 8.16 Hz, 1H, He), 7.69 (d, J = 7.54 Hz, 2H, Hb' and Hf'), 8.95 (d, J = 8.26 Hz, 1H, Hg) and 10.38 (s, 1H, Hh); <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>) δ (ppm): 115.2 (1C, Cd), 115.5 (2C, Cc' and Ce'), 121.0 (1C, Cb), 121.4 (1C, Cf), 121.9 (2C, Cb' and Cf'), 129.4 (1C, Cg), 130.3 (1C, Ca'), 134.5 (1C, Ce), 148.2 (1C, Cd'), 155.4 (1C, Cc) and 167.9 (1C, Ca).

*N,N*-diethyl-*m*-toluamide or DEET (Compound T2)


Yellow liquid 0.51 g (89 %),  $R_f$  0.45 (50 % EtOAc/hexane). IR (neat): 3113, 2972, 1629, 1564, 1418 and 1357  $\text{cm}^{-1}$ ;  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  (ppm): 1.08 (s (br), 3H,  $\text{CH}_2\text{CH}_3$ ), 1.17 (s (br), 3H,  $\text{CH}_2\text{CH}_3$ ), 2.30 (s, 3H,  $\text{ArCH}_3$ ), 3.21 (s (br), 2H,  $\text{CH}_2$ ), 3.46 (s (br), 2H,  $\text{CH}_2$ ) and 7.01-7.25 (m, 4H,  $\text{ArH}$ );  $^{13}\text{C-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  (ppm): 12.8 (1C,  $\text{Cb}'$ ), 14.1 (1C,  $\text{Cb}''$ ), 21.2 (1C,  $\text{ArCH}_3$ ), 39.1 (1C,  $\text{Ca}'$ ), 43.2 (1C,  $\text{Ca}''$ ), 123.0 (1C,  $\text{Cg}$ ), 126.7 (1C,  $\text{Cc}$ ), 128.1 (1C,  $\text{Cf}$ ), 129.7 (1C,  $\text{Ce}$ ), 137.1 (1C,  $\text{Cb}$ ), 138.0 (1C,  $\text{Cd}$ ) and 171.3 (1C,  $\text{Ca}$ ).

*Niclosamide* (Compound T3)


Pale yellow needle crystal 0.39 g (39 %), m.p. 231-232 °C (EtOH/H<sub>2</sub>O) (lit.<sup>48</sup> 233 °C),  $R_f$  0.62 (EtOAc). IR (KBr): 3564-3279, 3322, 3081, 1649, 1590, 1523, 1431, 1349, 1315 and 1011  $\text{cm}^{-1}$ ;  $^1\text{H-NMR}$  ( $\text{DMSO-d}_6$ )  $\delta$  (ppm): 1.57 (s, 1H,  $\text{NH}$ ), 6.82 (d,  $J = 9.09$  Hz, 1H,  $\text{Hd}$ ), 6.98 (d,  $J = 8.92$  Hz, 1H,  $\text{He}$ ), 7.54 (d,  $J = 8.83$  Hz, 1H,  $\text{Hb}'$ ), 7.71 (s, 1H,  $\text{Hg}$ ), 7.94 (d,  $J = 9.08$  Hz, 1H,  $\text{Hc}'$ ), 8.07 (s, 1H,  $\text{He}'$ ) and 10.42 (s, 1H,  $\text{OH}$ );  $^{13}\text{C-NMR}$  ( $\text{DMSO-d}_6$ )  $\delta$  (ppm): 113.7 (1C,  $\text{Cd}$ ), 114.4 (1C,  $\text{Cc}'$ ), 117.7 (1C,  $\text{Cb}$ ), 119.2 (1C,  $\text{Cb}'$ ), 122.5 (1C,  $\text{Ce}'$ ), 124.3 (1C,  $\text{Cf}$ ), 125.9 (1C,  $\text{Cf}'$ ), 129.1 (1C,  $\text{Cg}$ ), 135.1 (1C,  $\text{Ce}$ ), 144.6 (1C,  $\text{Ca}'$ ), 148.7 (1C,  $\text{Cd}'$ ), 159.6 (1C,  $\text{Cc}$ ) and 164.8 (1C,  $\text{Ca}$ ).

*N,N*-Diethyl-1-Naphthamide (Compound T4)


Yellow liquid 0.65 g (95 %),  $R_f$  0.54 (50 % EtOAc/hexane). IR (neat): 3052, 2965, 1644, 1629, 1509, 1475 and 1296  $\text{cm}^{-1}$ ;  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  (ppm): 0.97 (t,  $J = 7.09$  Hz, 3H,  $\text{CH}_3$ ), 1.35 (t,  $J = 7.09$  Hz, 3H,  $\text{CH}_3$ ), 3.08 (q,  $J = 7.09$  Hz, 2H,  $\text{CH}_2$ ), 3.54 (s (br), 2H,  $\text{CH}_2$ ) and 7.35-7.85 (m, 7H, ArH);  $^{13}\text{C-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  (ppm): 13.1 (1C, Cb'), 14.3 (1C, Cb''), 39.1 (1C, Ca'), 43.1 (1C, Ca''), 123.2 (1C, Ck), 124.7 (1C, Cj), 125.1 (1C, Cf), 126.4 (1C, Ce), 126.9 (1C, Cd), 128.3 (1C, Cg), 128.7 (1C, Ci), 129.6 (1C, Cc), 133.5 (1C, Ch), 135.1 (1C, Cb) and 170.3 (1C, Ca).

*N*-(2,6-dimethylphenyl)-4-methoxybenzamide (Compound T5)


White needle crystal 0.52 g (68 %), m.p. 164-166  $^\circ\text{C}$  ( $\text{CH}_2\text{Cl}_2$ /hexane) (lit.<sup>49</sup> 168-170  $^\circ\text{C}$ ),  $R_f$  0.47 (50 % EtOAc/hexane). IR (KBr): 3250, 3003, 2945, 2834, 1644, 1610, 1533, 1494, 1441 and 1306  $\text{cm}^{-1}$ ;  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  (ppm): 1.58 (s, 1H, NH), 2.26 (s, 6H,  $\text{CH}_3$ ), 3.86 (s, 3H,  $\text{OCH}_3$ ), 6.45 (t,  $J = 6.99$  Hz, 1H, Hd'), 6.83 (d,  $J = 7.39$  Hz, 2H, Hc' and He'), 6.96 (d,  $J = 8.67$  Hz, 2H, Hd and Hf) and 7.87 (d,  $J = 8.69$  Hz, 2H, Hc and Hg);  $^{13}\text{C-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  (ppm): 15.3 (2C,  $\text{CH}_3$ ), 55.5 (1C,  $\text{OCH}_3$ ), 113.9 (2C, Cd and Cf), 123.7 (1C, Cd'), 126.7 (1C, Cb), 127.3 (2C, Cc' and Ce'), 128.3 (2C, Cc and Cg), 129.1 (2C, Cb' and Cf'), 135.6 (1C, Ca'), 162.5 (1C, Ca) and 165.4 (1C, Ce).

*N*-(3,4-Methylenedioxy-cinnamoyl)piperidide (Compound T6)


Colorless needle crystal 0.73 g (94 %), m.p. 85-87 °C (CH<sub>2</sub>Cl<sub>2</sub>/hexane) (lit.<sup>50</sup> 89 °C), R<sub>f</sub> 0.30 (50 % EtOAc/hexane). IR (KBr): 3166, 2935, 2857, 1730, 1643, 1601, 1495, 1359 and 1250 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 1.61 (s (br), 6H, Hb', Hc' and Hd'), 3.59 (s (br), 4H, Ha' and He'), 5.93 (s, 2H, OCH<sub>2</sub>O), 6.71-6.79 (m, 3H, ArH), 6.98 (d, J = 14.93 Hz, 1H, HC=CHCO) and 7.54 (d, J = 15.33 Hz, 1H, CH=CHCO); <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ (ppm): 24.5 (1C, Cb'), 25.5 (1C, Cd'), 26.6 (1C, Cc'), 43.2 (1C, Ca'), 46.8 (1C, Ce'), 101.3 (1C, OCH<sub>2</sub>O), 106.2 (1C, Ce), 108.2 (1C, Ch), 115.6 (1C, Ci), 123.4 (1C, Cb), 129.7 (1C, Cd), 141.7 (1C, Cc), 148.1 (1C, Cg), 148.7 (1C, Cf) and 165.2 (1C, Ca).

*N*-(3,4,5-Trimethoxycinnamoyl)piperidide (Compound T7)

Colorless needle crystal 0.81 g (89 %), m.p. 100-101 °C (CH<sub>2</sub>Cl<sub>2</sub>/hexane) (lit.<sup>51</sup> 97.5-100 °C), R<sub>f</sub> 0.44 (50 % EtOAc/hexane). IR (KBr): 3061, 2931, 2844, 1717, 1639, 1581, 1436 and 1330 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 1.57 (s (br), 6H, Hb', Hc' and Hd'), 3.51 (s (br), 4H, Ha' and He'), 3.86 (s, 9H, OCH<sub>3</sub>), 6.74 (s, 2H, ArH), 6.93 (d, J = 15.81 Hz, 1H, HC=CHCO) and 7.65 (d, J = 15.95 Hz, 1H, CH=CHCO); <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ (ppm): 24.5 (1C, Cb'), 25.6 (1C, Cd'), 26.8 (1C, Cc'), 43.4 (1C, Ca'), 47.0 (1C, Ce'), 56.2 (2C, Cj and Ci), 60.4 (1C, Ck), 104.8 (2C, Ce and Ci), 116.9 (1C, Cb), 131.1 (1C, Cd), 133.4 (1C, Cg), 142.3 (1C, Cc), 153.3 (2C, Cf and Ch) and 165.3 (1C, Ca).


***N-Feruloyltyramine*** (Compound T8)

Colorless needle crystal 0.49 g (52 %), m.p. 145-147 °C (CH<sub>2</sub>Cl<sub>2</sub>/MeOH) (lit<sup>52</sup> 143-145 °C), R<sub>f</sub> 0.51 (EtOAc). IR (KBr): 3656-3284, 3329, 3090, 2940, 2848, 1726, 1630, 1596, 1509, 1465, 1417 and 1267 cm<sup>-1</sup>; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ (ppm): 1.17 (t, J = 7.20 Hz, 1H, NH), 2.75 (t, J = 7.86 Hz, 2H, Hb'), 3.01 (q, J = 7.22 Hz, 2H, Ha'), 3.78 (s, 3H, OCH<sub>3</sub>), 6.34 (d, J = 15.88 Hz, 1H, CH=CHCO), 6.71 (d, J = 8.06 Hz, 2H, He' and Hg'), 6.80 (d, J = 8.24 Hz, 1H, Hh), 7.02 (d, J = 7.82 Hz, 2H, Hd' and Hh'), 7.23 (s, 1H, He), 7.45 (d, J = 15.92 Hz, 1H, CH=CHCO) and 7.56 (d, J = 8.56 Hz, 1H, Hi). <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>) δ (ppm): 32.1 (1C, Cb'), 45.3 (1C, Ca'), 55.6 (1C, OCH<sub>3</sub>), 111.0 (1C, Ce), 115.3 (2C, Ce' and Cg'), 116.2 (1C, Ch), 122.6 (1C, Cb), 125.8 (1C, Ci), 127.3 (1C, Cd), 129.5 (2C, Cd' and Ch'), 143.5 (1C, Cc'), 144.0 (1C, Cc), 147.9 (1C, Cg), 149.0 (1C, Cf), 156.1 (1C, Cf') and 168.3 (1C, Ca).


***Idrocilamide*** (Compound T9)

White needle crystal 0.19 g (33 %), m.p. 98-99 °C (MeOH/H<sub>2</sub>O) (lit<sup>53</sup> 97 °C), R<sub>f</sub> 0.64 (EtOAc). IR (KBr): 3644-3285, 3230, 3057, 2916, 1728, 1637, 1532, 1437 and 1346 cm<sup>-1</sup>; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ (ppm): 1.22 (s (br), 1H, NH), 3.35-3.48 (m, 4H, alkyl H), 3.95 (s, 1H, OH), 6.72 (d, J = 16.16 Hz, 1H, CH=CHCO), 7.17 (d, J = 16.53 Hz, 1H, CH=CHCO) and 7.32-7.76 (m, 5H, ArH); <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>) δ (ppm): 46.0 (1C, Ca'), 64.5 (1C, Cb'), 120.6 (1C, Cb), 127.8 (2C, Ce and Ci), 128.7 (1C, Cg), 129.3 (2C, Cf and Ch), 135.4 (1C, Cd), 142.4 (1C, Cc) and 165.2 (1C, Ca).



**Fagaramide (Compound T10)**

White needle crystal 0.49 g (69 %), m.p. 119-120 °C (CH<sub>2</sub>Cl<sub>2</sub>/hexane) (lit<sup>54</sup> 119-120 °C), R<sub>f</sub> 0.46 (50 % EtOAc/hexane). IR (NaCl plates): 3289, 3076, 2965, 1644, 1615, 1547, 1494, 1330 and 1243 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 0.93 (d, J = 6.67 Hz, 6H, CH<sub>3</sub>), 1.57 (s, 1H, NH), 1.75-1.88 (m, 1H, CH(CH<sub>3</sub>)<sub>2</sub>), 3.19 (t, J = 6.24 Hz, 2H, NHCH<sub>2</sub>), 5.97 (s, 2H, OCH<sub>2</sub>O), 6.19 (d, J = 15.49 Hz, 1H, HC=CHCO), 6.77 (d, J = 7.61 Hz, 1H, H<sub>h</sub>), 6.96 (d, J = 7.53 Hz, 1H, H<sub>i</sub>), 6.99 (s, 1H, H<sub>e</sub>) and 7.51 (d, J = 15.56 Hz, 1H, CH=CHCO). <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ (ppm): 20.2 (2C, Cc' and Cd'), 28.6 (1C, Cb'), 47.1 (1C, Ca'), 101.4 (1C, OCH<sub>2</sub>O), 106.3 (1C, Ce), 108.5 (1C, Ch), 118.8 (1C, Ci), 123.8 (1C, Cb), 129.3 (1C, Cd), 140.6 (1C, Cc), 148.2 (1C, Cg), 148.9 (1C, Cf) and 166.1 (1C, Ca).

**2-Chloro-N,N-diethyl-cinnamamide (Compound T11)**

Yellow liquid 0.83 g (70 %), R<sub>f</sub> 0.41 (50 % EtOAc/hexane). IR (neat): 3061, 2979, 1639, 1601, 1564, 1465, 1364 and 1046 cm<sup>-1</sup>; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ (ppm): 1.06 (t, J = 7.03 Hz, 3H, H<sub>b'</sub>), 1.13 (t, J = 6.97 Hz, 3H, H<sub>b''</sub>), 3.43 (q, J = 6.99 Hz, 2H, H<sub>a'</sub>), 3.54 (q, J = 6.93 Hz, 2H, H<sub>a''</sub>), 7.13 (d, J = 15.34 Hz, 1H, HC=CHCO), 7.35-7.52 (m, 4H, ArH) and 7.79 (d, J = 15.32 Hz, 1H, CH=CHCO). <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>) δ (ppm): 18.3 (1C, C<sub>b'</sub>), 20.4 (1C, b''), 45.6 (1C, C<sub>a'</sub>), 46.7 (1C, C<sub>a''</sub>), 126.9 (1C, C<sub>b</sub>), 132.7 (1C, C<sub>h</sub>), 133.4 (1C, C<sub>i</sub>), 134.9 (1C, C<sub>f</sub>), 136.0 (1C, C<sub>g</sub>), 138.1 (1C, C<sub>e</sub>), 138.5 (1C, C<sub>d</sub>), 141.3 (1C, C<sub>c</sub>) and 169.3 (1C, C<sub>a</sub>).